Kymriah - Medicine bibliographies - in Harvard style

In-text: (Brennan, 2022)

Your Bibliography: Brennan, Z., 2022. HHS inspector general signs off on Novartis paying for pricey Kymriah. [online] Endpoints News. Available at: <https://endpts.com/hhs-inspector-general-signs-off-on-novartis-paying-for-pricey-kymriah/> [Accessed 9 October 2022].

In-text: (CAR T-cell Therapy and Its Side Effects, 2022)

Your Bibliography: Cancer.org. 2022. CAR T-cell Therapy and Its Side Effects. [online] Available at: <https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/car-t-cell1.html> [Accessed 8 October 2022].

In-text: (Carroll, 2022)

Your Bibliography: Carroll, J., 2022. Novartis may still be grappling with Kymriah sales, but historic CAR-T promise still shines through 5-year data. [online] Endpoints News. Available at: <https://endpts.com/novartis-may-still-be-grappling-with-kymriah-sales-but-historic-car-t-promise-still-shines-through-5-year-data/> [Accessed 13 October 2022].

In-text: (Kymriah (tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukaemia, USA, 2022)

Your Bibliography: Clinical Trials Arena. 2022. Kymriah (tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukaemia, USA. [online] Available at: <https://www.clinicaltrialsarena.com/projects/kymriah-tisagenlecleucel-for-the-treatment-of-acute-lymphoblastic-leukaemia/> [Accessed 8 October 2022].

In-text: (Food and Drug Administration (FDA), 2017)

Your Bibliography: Food and Drug Administration (FDA), 2017. Summary Basis for Regulatory Action. Washington, DC: FDA.

In-text: (Hill, Artiga and Haldar, 2022)

Your Bibliography: Hill, L., Artiga, S. and Haldar, S., 2022. Key Facts on Health and Health Care by Race and Ethnicity. [online] KFF. Available at: <https://www.kff.org/racial-equity-and-health-policy/report/key-facts-on-health-and-health-care-by-race-and-ethnicity/> [Accessed 8 October 2022].

In-text: (Updated Data on Blood Cancers, 2022)

Your Bibliography: Lls.org. 2022. Updated Data on Blood Cancers. [online] Available at: <https://www.lls.org/sites/default/files/2021-08/PS80%20FactsBook_2020_2021_FINAL.pdf> [Accessed 8 October 2022].

In-text: (NCI Dictionary of Cancer Terms, 2022)

Your Bibliography: National Cancer Institute. 2022. NCI Dictionary of Cancer Terms. [online] Available at: <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/kymriah> [Accessed 8 October 2022].

In-text: (Gene therapy’s next installment, 2019)

Your Bibliography: Nature Biotechnology, 2019. Gene therapy’s next installment. 37(7), pp.697-697.

In-text: (Novartis, 2018)

Your Bibliography: Novartis, 2018. Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma. [online] Available at: <https://www.novartis.com/news/media-releases/kymriah-tisagenlecleucel-first-class-car-t-therapy-from-novartis-receives-second-fda-approval-treat-appropriate-rr-patients-large-b-cell-lymphoma> [Accessed 8 October 2022].

In-text: (Pagliarulo, 2022)

Your Bibliography: Pagliarulo, N., 2022. Rare case of CAR-T resistance underscores manufacturing hurdles. [online] BioPharma Dive. Available at: <https://www.biopharmadive.com/news/rare-case-of-car-t-resistance-underscores-manufacturing-hurdles/538643/> [Accessed 13 October 2022].

In-text: (Drug and device news: New drug approvals, 2022)

Your Bibliography: Pharmacy and Therapeutics, 2022. Drug and device news: New drug approvals. [online] 42(10), pp.608-613,618-619,650-651. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5614410/> [Accessed 8 October 2022].

In-text: (The 100 greatest innovations of 2017, 2022)

Your Bibliography: Popular Science. 2022. The 100 greatest innovations of 2017. [online] Available at: <https://www.popsci.com/best-of-whats-new-list-2017/> [Accessed 8 October 2022].

In-text: (Styczyński, 2020)

Your Bibliography: Styczyński, J., 2020. A brief history of CAR-T cells: from laboratory to the bedside. Acta Haematologica Polonica, 51(1), pp.2-5.

In-text: (Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice, 2022)

Your Bibliography: Teletrader.com. 2022. Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice. [online] Available at: <https://www.teletrader.com/novartis-receives-first-ever-fda-approval-for-a-car-t-cell-t/news/details/40159875?ts=1665246083077> [Accessed 8 October 2022].

In-text: (Kymriah cost dispute goes to heart of pharma's pricing row, 2022)

Your Bibliography: Thepharmaletter.com. 2022. Kymriah cost dispute goes to heart of pharma's pricing row. [online] Available at: <https://www.thepharmaletter.com/article/novartis-overpricing-kymriah-by-nearly-200-says-journal-report> [Accessed 13 October 2022].